BC3 Technologies, a Baltimore-based, minority-owned company revolutionising emergency medical response and trauma care, has annoucned that its SEAL hemostatic wound spray can now be used by Maryland EMS clinicians to help stop blood loss fast.
In December 2024, the Maryland Institute for Emergency Medical Services Systems (MIEMSS) declared all FDA-approved/FDA-cleared chitosan or kaolin based hemostatic agents will be permitted in Maryland for the purposes of hemorrhage control.
“We recognise that hemorrhage control for injured patients is of paramount importance. Whether the bleeding is controlled with a gloved hand, gauze, or a tourniquet, every minute counts for the patients,” said Timothy Chizmar, MD, State EMS nmedical director, MIEMSS.
While some bleeding can be controlled by hand or gauze, many wounds prove to be more challenging to manage. MIEMSS and other groups of experts in trauma surgery and emergency medicine reviewed hemostatic agents in various forms including powder and spray that are currently available to the EMS community.
“We are fortunate that Maryland is a forward-leaning, highly data-driven EMS system. With alterations and adjustments to protocol or EMS initiatives based on positive patient outcomes. MIEMSS examined our research, along with deployments internationally, and provided products to the University of Maryland Shock Trauma Center. They analysed the data from our studies and FDA clearance documents, validated our products, and informed MIEMSS that SEAL was acceptable for trauma care in Maryland,” said Wayne Grube, CEO and Co-Founder, BC3 Technologies.
“As a result of the assessment, Maryland EMS clinicians may now utilise a chitosan- or kaolin-based hemostatic agent, which is FDA-approved or FDA-cleared, for hemorrhage control. The hemostatic agent may be embedded in gauze or packaged in another form (e.g. spray or gel). Individual hemostatic products should be reviewed with county or service medical directors prior to implementation,” added Chizmar.
Now all Maryland EMS clinicians have consent to utilise SEAL as part of their protocols to stop blood loss fast.
“This protocol change opens many doors for BC3 Technologies. Maryland is leading the way in improving patient outcomes by seeing SEAL as the innovative breakthrough that will save lives. With a Maryland EMS deployment, we are encouraging others to follow,” continued Grube.
SEAL Hemostatic Would Spray is the first and only FDA-cleared aerosolised chitosan for rapid management of serious arterial bleeding.
Seal Hemostatic Wound Spray approved by Maryland Emergency Medical Services
